Aflibercept 2 mg Biosimilar (aflibercept-ayyh, Pavblu): Experience of safety in clinical settings-APEX- safety study.
- DOI
- 10.1038/s41433-026-04327-1
- Published
- 2026 Apr
- Container
- Eye (London, England)
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1038/s41433-026-04327-1,
title = {Aflibercept 2 mg Biosimilar (aflibercept-ayyh, Pavblu): Experience of safety in clinical settings-APEX- safety study.},
author = {Sharma A and Khanani AM and Eichenbaum D and Boyer D and Shaer A and Ortiz T and Sulahria H and Flores A and Regillo C and and the Inter BIOS Group},
year = {2026},
journal = {Eye (London, England)},
doi = {10.1038/s41433-026-04327-1},
url = {https://doi.org/10.1038/s41433-026-04327-1}
}RIS
TY - JOUR TI - Aflibercept 2 mg Biosimilar (aflibercept-ayyh, Pavblu): Experience of safety in clinical settings-APEX- safety study. AU - Sharma A AU - Khanani AM AU - Eichenbaum D AU - Boyer D AU - Shaer A AU - Ortiz T AU - Sulahria H AU - Flores A AU - Regillo C AU - and the Inter BIOS Group PY - 2026 JO - Eye (London, England) DO - 10.1038/s41433-026-04327-1 UR - https://doi.org/10.1038/s41433-026-04327-1 ER -
APA
A, S., AM, K., D, E., D, B., A, S., T, O., H, S., A, F., C, R., & Group, A. T. I. B. (2026). Aflibercept 2 mg Biosimilar (aflibercept-ayyh, Pavblu): Experience of safety in clinical settings-APEX- safety study.. Eye (London, England). https://doi.org/10.1038/s41433-026-04327-1
Source records
- pubmed · retrieved 2026-09-26T07:45:26.663Z